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Abstract
Gammaherpesviruses such as KSHV and EBV establish lifelong persistent infections through latency in lymphocytes. These
viruses have evolved several strategies to counteract the various components of the innate and adaptive immune systems.
We conducted an unbiased screen using the genetically and biologically related virus, MHV-68, to find viral ORFs involved in
the inhibition of type I interferon signaling and identified a conserved viral dUTPase, ORF54. Here we define the
contribution of ORF54 in type I interferon inhibition by ectopic expression and through the use of genetically modified
MHV-68. ORF54 and an ORF54 lacking dUTPase enzymatic activity efficiently inhibit type I interferon signaling by inducing
the degradation of the type I interferon receptor protein IFNAR1. Subsequently, we show in vitro that the lack of ORF54
causes a reduction in lytic replication in the presence of type I interferon signaling. Investigation of the physiological
consequence of IFNAR1 degradation and importance of ORF54 during MHV-68 in vivo infection demonstrates that ORF54
has an even greater impact on persistent infection than on lytic replication. MHV-68 lacking ORF54 expression is unable to
efficiently establish latent infection in lymphocytes, although it replicates relatively normally in lung tissues. However,
infection of IFNAR2/2 mice alleviates this phenotype, emphasizing the specific role of ORF54 in type I interferon inhibition.
Infection of mice and cells by a recombinant MHV-68 virus harboring a site specific mutation in ORF54 rendering the
dUTPase inactive demonstrates that dUTPase enzymatic activity is not required for anti-interferon function of ORF54.
Moreover, we find that dUTPase activity is dispensable at all stages of MHV-68 infection analyzed. Overall, our data suggest
that ORF54 has evolved anti-interferon activity in addition to its dUTPase enzymatic activity, and that it is actually the anti-
interferon role that renders ORF54 critical for establishing an effective persistent infection of MHV-68.
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Introduction
Virus infection induces numerous immune responses in the host,
the earliest of which is the innate immune response [1,2]. The
innate immune response is comprised of many layers of non-
specific defense, including anatomical barriers, such as skin and
mucosa, the complement system, inflammation, and various cells,
such as natural killer cells, phagocytes, mast cells, macrophages,
dendritic cells, neutrophils, and basophils [3–5]. The innate
immune response plays a crucial role in shaping the ensuing
adaptive immune response, in part by the production of cytokines
in response to infection [2,6]. Interferons (IFN) are cytokines
secreted upon virus infection that induce the expression of a
variety of antiviral gene products, reducing virus replication and
further infection [1,7–9].
Interferons are classified as type I and II, as defined by the cell
types able to produce them and the receptors they bind to [1].
Unlike the type II IFN-c that is produced by specific cells of the
immune system, IFN-a and IFN-b are type I IFNs that can be
produced in most cell types [10]. Mammals encode a single IFN-b
and several IFN-a species. All type I IFN species bind to the same
ubiquitously expressed receptor, called the type I interferon
receptor, or IFNAR [11]. This receptor is a heterodimer
comprised of IFNAR1 and IFNAR2 [12]. Although normally
unassociated, IFNAR1 and IFNAR2 dimerize upon the binding of
IFN-a or IFN-b first to IFNAR2, and then to both receptors in the
dimer [13]. IFNAR1 and IFNAR2 are each pre-associated with
one of the members of the Janus protein tyrosine kinase family,
where TYK2 is associated with IFNAR1 and JAK1 with IFNAR2.
IFN binding and formation of the complete IFNAR dimer leads to
cross-phosphorylation of TYK2 and JAK1, and the phosphory-
lation of the IFNAR chains they are permanently associated with.
These phosphorylation events set up a platform for the
recruitment of STAT1 and STAT2, which in turn are also
phosphorylated. The phosphorylated STAT proteins dimerize
prior to joining with IFN-regulatory factor 9 (IRF9) to form the
Interferon-Stimulated Gene Factor 3 (ISGF3c) transcription
factor, which translocates to the nucleus where it induces the
expression of hundreds of interferon stimulatory genes (ISG)
(reviewed in [1]).
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by their ability to persist for the lifetime of the host by establishing
latent infections and by evading the host immune response [14].
Both lytic and latent infections of herpesviruses are able to directly
cause disease [15–23]. Gaining understanding of the mechanisms
by which herpesviruses maintain persistent infections and evade
immune surveillance is a key step in controlling the diseases they
are associated with. Herpesviruses are subdivided into alpha, beta,
and gamma herpesviruses [14]. The human gammaherpesviruses
are Epstein-Barr virus (EBV) and Kaposi’s sarcoma-associated
herpesvirus (KSHV). Both EBV and KSHV are associated with
malignancies; EBV with Burkitt’s lymphoma, nasopharyngeal
carcinoma, and oral hairy leukoplakia and KSHV with Kaposi’s
sarcoma, primary effusion lymphoma, and multicentric Castle-
man’s disease [23–28]. We use the biologically and genetically
related virus, murine gammaherpesvirus-68 (MHV-68) as a model
to study the human gammaherpesviruses [29–32]. Like KSHV,
MHV-68 is a gamma-2-herpesvirus. MHV-68 establishes lytic and
latent infections in mice [33], replicates readily in in vitro cell
culture systems, and has a genome that can be genetically
manipulated by utilizing a bacterial artificial chromosome (BAC)
system [34].
In KSHV and MHV-68 several studies have identified viral
proteins involved in the inhibition of the host innate and adaptive
immune responses. In particular,KSHV open readingframe (ORF)
10 binds to JAK and STAT proteins to block IFN mediated
signaling [35]. KSHV and MHV-68 ORF36 bind to phosphory-
lated IRF3, thus inhibiting the production of IFN-b [36]. KSHV
ORF45 interacts with and inhibits IRF7 from entering the cell
nucleus [37]. The KSHV immediate early transcription factor and
E3 ligase, RTA, targets IRF7 for protein degradation [38]. Other
viral ORFs also contribute to immune evasion by inducing the
downregulation of surface molecules critical for immune activation.
K5 of KSHV directs the downregulation of Tetherin/BST2,
ICAM, and MHC class I [39–42]. Furthermore, K3 of both KSHV
and MHV-68 inhibit the surface expression of MHC class I [39,43].
29-deoxyuridine 59-triphosphate pyrophosphatase (dUTPase)
reduces the misincorporation of uracil in the DNA genome by
controlling the level of dUTP through conversion of dUTP into
dUMP, ultimately leading to an increased amount of dTTP and a
lower dUTP:dTTP ratio [44]. This enzyme can be found in all
classes of organisms and in many RNA and DNA viruses as well
[45,46]. In this study, we define the role of viral ORF54, a
functional dUTPase, in evading the host innate immune response
to virus infection. In an effort to understand these two separate
functions of ORF54, we analyzed the signaling pathways altered
by wild-type ORF54 and a dUTPase-null mutant. Through in vitro
and in vivo infection, in wild-type and transgenic mice, with
recombinant MHV-68 harboring mutations in ORF54, we found
that ORF54 interferes with-type I interferon signaling, which
further affects persistent infection and the establishment of latency.
Results
Identification of ORF54 as an inhibitor of the type I
interferon response
To systematically identify MHV-68 viral ORFs that inhibit type
I IFN signaling, we conducted a screen where 293T cells were
transiently transfected with a reporter construct containing firefly
luciferase driven by the interferon-stimulated response element
(ISRE_firefly-luciferase). Cells were also co-transfected with a
reporter construct containing renilla luciferase driven by the
constitutively active PGK promoter and each MHV-68 viral ORF
or a vector control. Transfected cells were treated with human
IFN-a and the induction of the ISRE reporter was measured by
dual luciferase assay. Since this screen examines cellular responses
after IFN-a treatment, the viral proteins previously identified to
inhibit IRF3 or IRF7 signaling, thus preventing the induction of
type I IFN production, would not necessarily be identified. Of all
the MHV-68 viral ORFs that were screened, we found 8 ORFs
that were potentially able to inhibit type I IFN signaling to a level
that is 50% of the activation seen with vector control. Two of them
are M2 and M8, ORFs specific to MHV-68. M2 has been
previously shown to inhibit IFN signaling [47], thus validating our
screen. Among the other 6 ORFs that also have homologues in
KSHV and EBV, ORFs 10, 11, and 54 are particularly interesting
because a previous sequence analysis study identified a shared
dUTPase-related domain, although only ORF54 contains catalytic
active sites [48]. Since ORF54 is a viral dUTPase and is one of the
top three strongest inhibitors, our following study focuses on its
potential anti-IFN function and the biological significance of this
function during viral infection. Cells transfected with ORF54
demonstrated a diminished activation of ISRE following treatment
with IFN-a (Figure 1), with only 20% of the activation seen in
control transfections. KSHV ORF54 also demonstrated dimin-
ished activation of ISRE, at 23% of control (Figure 1), suggesting
that the ability to inhibit type I IFN signaling is a gammaherpes-
virus conserved function of ORF54.
ORF54 inhibition of the type I interferon response is
independent of enzymatic activity
To test whether the dUTPase function is required for the anti-
IFN activity of ORF54, we constructed a catalytic domain mutant
of MHV-68 ORF54 by replacing the amino acid histidine at
position 80 with alanine and the amino acid aspartic acid at
position 85 with asparagine (ORF54 H80A/D85N). These two
amino acids were chosen for mutagenesis due to their proximal
location in the putative active site of ORF54 dUTPase and their
predicted importance for enzymatic reaction. Viral and non-viral
dUTPases typically share five highly conserved motifs, although
the arrangement found in herpesviruses is different compared to
human dUTPase [44,48]. Several studies have identified the
Author Summary
Human gammaherpesviruses, Kaposi’s sarcoma-associated
herpesvirus and Epstein-Barr virus, are the cause of several
malignancies, especially in patients immunocompromised
due to HIV infection. The study of these human
gammaherpesviruses is difficult due to their inability to
replicate in cell culture and the lack of a small-animal
model. Murine gammaherpesvirus-68 is a genetically and
biologically similar virus that is utilized as a mouse model
because it offers such advantages as the ability to replicate
in cell culture, a manipulatable genome, and infection of
mice. In this study, we have identified viral open reading
frame 54 (ORF54) as an inhibitor of innate immunity,
specifically of the type I interferon response. Although
ORF54 is a conserved viral dUTPase, we found that its anti-
interferon activity does not require its enzymatic activity.
Through infection of cells and mice, we define the critical
role of ORF54 in establishing persistent latent infection of
MHV-68 by inducing the degradation of the type I
interferon receptor. Our studies provide new insights into
the far reaching effects of type I interferon signaling and
the dual role of ORF54. This work could aid in the
development of vaccine strategies to gammaherpesvirus
infection.
A Conserved dUTPase has Critical Anti-IFN Activity
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activity, in the herpesvirus dUTPases [44]. Aspartic acid at
position 85, located in motif III, was altered because aspartic acids
at positions 84 and 86 in human endogenous retrovirus (HERV-K)
were found to be critical for catalytic activity, but not for dUTP
binding [44]. Histidine at position 80 was chosen because it is
conserved in gammaherpesviruses, and in EBV a histidine at
position 71 contains a necessary imidazole group [49]. The
ORF54 H80A/D85N mutant demonstrates a complete loss in
enzymatic activity, although the protein expression level remained
the same (Figure 2). When co-transfected with ISRE_firefly-
luciferase, ORF54 H80A/D85N maintains the ability to diminish
IFN-a induced activation of the ISRE to 32% of the activation
seen in control samples (Figure 1). This result suggests ORF54
inhibition of the type I IFN signaling cascade is independent of its
dUTPase enzymatic activity. To further clarify if the dUTPase
function was sufficient to inhibit type I IFN signaling, we tested the
ability of murine cellular dUTPase to inhibit IFN-a induced
activation of ISRE in our reporter assay. The cellular dUTPase
was unable to block activation of ISRE_firefly-luciferase (Figure 1),
further indicating that dUTPase enzymatic activity does not
necessarily correlate with anti-IFN activity.
ORF54 induces the degradation of the type I interferon
receptor 1
The type I IFN signaling pathway begins with the binding of
IFN-a to the surface IFNAR and results in the production of ISGs
[7,8]. As each step in the JAK/STAT pathway that ensues is well
defined [1], we aimed to identify the step where ORF54 exerts its
function. We first assayed a central event in type I IFN signaling,
the phosphorylation of STAT1 protein. 293T cells ectopically
overexpressing MHV-68 ORF54 or ORF54 H80A/D85N both
demonstrated a reduced level of phosphorylation of STAT1
following treatment by IFN-a in comparison to cells transfected
with vector control or an unrelated MHV-68 ORF (Figure 3A). By
assay of steps upstream of the phosphorylation of STAT1, we
show that cells expressing MHV-68 ORF54 or ORF54 H80A/
D85N both demonstrated a reduced level of total IFNAR1
(Figure 3B). As a control for specificity, we also found that ORF54
and ORF54 H80A/D85N do not alter levels of the surface
protein type I insulin-like growth factor receptor-b (IGF1b)o r
IFNAR2 (Figure 3B). These results suggest that ORF54 induces
the degradation of IFNAR1 independently of its dUTPase enzyme
activity, and that this degradation results in a reduction of the type
I IFN response, including the phosphorylation of STAT1. The
transcript level of IFNAR1 remains comparable between the
vector control and viral ORF transfected cells (Figure 3C),
suggesting that the ORF54 induced reduction of IFNAR1 is at
the protein level.
ORF54 plays a role in counteracting IFN during viral
replication
We generated three recombinant MHV-68 to study the
importance of ORF54 (Figure 4A). Because ORF54 is not
required for the virus to replicate in cultured cells [50], the first
mutant is an ORF54-null virus that has triple translational stop
codons inserted near the N-terminus of MHV-68 ORF54
(54Stop). The second virus is a revertant for 54Stop, where the
translational stop codons have been removed and reverted back to
wild type (54R). This virus ensures that any phenotype
demonstrated with 54Stop is due to the ORF54-null mutation
and not any additional recombination or unintentional mutagen-
esis of the MHV-68 viral genome. The third virus (54DM) has the
Figure 1. MHV-68 and KSHV ORF54 diminish IFN-a induced
activation of ISRE in a non-dUTPase related manner. HEK 293T
cells were transiently transfected with ISRE_firefly-luciferase, PGK_re-
nilla-luciferase as an internal control, and with expression plasmids for
each ORF, control plasmid, or murine cellular dUTPase, then were
treated with 3610
4 U/mL of human IFN-a. Firefly luciferase values were
normalized to renilla luciferase. Percentage of activation is calculated in
comparison to control, an unrelated MHV-68 ORF or vector control.
Error bars depict one standard error based on four independent trials.
doi:10.1371/journal.ppat.1002292.g001 Figure 2. Generation of a dUTPase-null MHV-68 ORF54. A)
Immunoblot against the FLAG epitope of immunoprecipitated ORFs or
control demonstrates equal amounts of each protein was purified from
transfected 293T cells and used in the dUTPase activity assay. B) A PCR
reaction utilizing individual dNTPs, with dUTP replacing dTTP, was used
to determine the presence of functional dUTP after incubation
(between 0 and 25 hours) with purified murine cellular dUTPase,
MHV-68 ORF 54, MHV-68 ORF54 H80A/D85N, and a vector control. The
presence of a PCR product indicates intact dUTP, and thus a non-
functional dUTPase.
doi:10.1371/journal.ppat.1002292.g002
A Conserved dUTPase has Critical Anti-IFN Activity
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in the ORF54 H80A/D85N expression construct (Figure 4A).
NIH3T3 cells were infected with an MOI of 2 to initiate single-
step growth kinetics. 24 hours post infection, cells were either
treated for 15 minutes with 500 units/mL of mouse IFN-a or left
untreated. Uninfected cells were also treated as a control.
Immunoblots probing for the phosphorylation of STAT1 protein
demonstrate that while wild-type (WT) MHV-68, 54DM, and 54R
are able to block STAT1 phosphorylation, higher levels of
phosphorylated STAT1 are found in cells infected with 54Stop
(Figure 4B). Total STAT1 is comparable in all samples and all cells
are infected to a similar level, as demonstrated by equal
production of the MHV-68 late protein ORF65. Therefore, this
result supports the role of ORF54 in the inhibition of type I IFN
signaling during viral infection, as lacking ORF54 partially
alleviates the block. However, we also noted that the phosphor-
ylated STAT1 seen in cells infected with 54Stop is still not at the
level observed in uninfected and treated cells. This is perhaps due
to the other viral ORFs that are present and still able to inhibit the
type I IFN signaling pathway, as evidenced by the multiple ORFs
identified in our original screen. As an additional control to
demonstrate that infected cells are still capable of responding to
stimuli, NIH3T3 cells were identically infected with an MOI of 2
and treated at 24 hours post infection with 160 mM prostratin (12-
deoxyphorbol 13-acetate) for 30 minutes (Figure 4B). Prostratin
initiates a signaling cascade that induces the reactivation of latent
viruses [51]. In this control assay, immunoblots probing for the
phosphorylation of p44/p42 (Erk1/2) demonstrate that infected
cells are viable enough to respond to stimuli even 24 hours post
infection. These studies demonstrate that although at this MOI the
54Stop virus can establish a robust viral infection, the lack of
functional ORF54 makes it unable to effectively block the resulting
induction of the type I IFN signaling cascade.
Since we showed the degradation of IFNAR1 in the presence of
overexpressed ORF54 (Figure 3B), we assayed this phenotype
during virus infection to determine the biological relevance. By
infecting cells with WT MHV-68 and 54R we found that IFNAR1
is degraded (Figure 4C). This degradation is reduced in cells
infected with 54Stop virus, suggesting that ORF54 is required for
the virus to induce degradation of IFNAR1. Furthermore, because
cells infected with 54DM virus show a similar level of IFNAR1
reduction as with WT or 54R infection, this indicates that ORF54
dUTPase enzymatic function is not required for the degradation of
IFNAR1 and the inhibition of the type I IFN signaling cascade.
Interestingly, unlike with STAT1 phosphorylation, we observed a
comparable level of IFNAR1 between 54Stop-infected cells and
uninfected cells, indicating that ORF54 is the sole viral protein
responsible for IFNAR1 degradation during viral infection. As a
control for specificity, we also found that virus infection does not
alter the levels of IFNAR2 or the surface protein IGF1-b
(Figure 4C). Therefore, ORF54 mediated degradation is not a
general phenomenon for all surface proteins and IFNAR1 is a
specific target for such ORF54 function. The transcript level of
IFNAR1 remains comparable amongst cells infected with WT,
54Stop, 54DM, and 54R viruses (Figure S1), suggesting that
Figure 3. ORF54 induces degradation of IFNAR1. 24 hours post
transfection, 293T cells were treated with 1 mg/mL of puromycin to
select for transfected cells. 48 hours post treatment, cells overexpress-
ing vector control or FLAG-tagged MHV-68 ORFs were: A) treated with
human IFN-a for 15 minutes. Immunoblot for phosphorylation of STAT1
on Tyr 701 was assayed first; the membrane was subsequently stripped
twice to demonstrate equal levels of total STAT1 and expression of
FLAG-ORFs as controls; B) Upper panels: Lysed to analyze level of
IFNAR1. The membrane was subsequently stripped to demonstrate
equal expression of the FLAG-ORFs and b-actin as controls, and IGF1b
to demonstrate specificity of ORF54 to IFNAR1. Lower panels: The same
lysates were also subjected to immunoblot against IFNAR2. The
membrane was stripped twice to demonstrate equal expression of
FLAG-ORFs and b-actin as controls. C) harvested for total RNA isolation.
Human IFNAR1 transcript levels were quantified by RT-PCR, normalized
first to actin, and are shown relative to vector control transfected cells.
Ctrl. is the vector control, ORF48 is an unrelated MHV-68 ORF used as a
negative control.
doi:10.1371/journal.ppat.1002292.g003
A Conserved dUTPase has Critical Anti-IFN Activity
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ORF54 induced degradation of IFNAR1 is at the protein level.
Because we found 54Stop defective in inhibiting type I IFN
signaling due to its inability to induce IFNAR1 degradation, we
assayed the downstream induction of ISGs following infection of
bone marrow derived macrophages. Macrophages were chosen for
infection due to their high endogenous induction of anti-viral
genes following virus infection. 24 hours post infection at an MOI
of 2, cells were harvested for immunoblot against the ISG IFIT2.
All infected cells show induced expression of IFIT2 compared to
uninfected cells. IFIT2 protein expression was highest in 54Stop
infected cells compared to in cells infected with WT, 54DM, and
54R (Figure 5A), suggesting a virus lacking functional ORF54 is
not as effective in blocking ISG induction as WT MHV-68.
Figure 4. An ORF54-null virus has incomplete degradation of IFNAR1. A) Schematic diagram depicting the construction of an MHV-68
ORF54 mutant with an insertion of a triple translational stop codon (54Stop), its revertant (54R), and a dUTPase-null double amino acid mutant with
ORF54 histidine at position 80 mutated to alanine and aspartic acid at position 85 mutated to asparagine (54DM). Nucleotide coordinates are based
on GenBank U97553. WT MHV-68 and 54R contain a BamHI restriction enzyme site that is altered to a HindIII site with the introduction of the triple
stop codon. The base pair changes in 54DM allow the introduction of an AseI site that is absent in WT MHV-68. Base changes are depicted in gray and
underlined; restriction enzyme recognition sites are bolded. B) Upper panels: NIH3T3 cells infected with each indicated virus at MOI 2 for 24 hours
were treated with murine IFN-a for 15 minutes and then harvested for immunoblot against phosphorylation of Tyr701 of STAT1. Blots were stripped
twice to demonstrate equal amounts of total STAT1 and comparable infection with expression of viral protein ORF65. Lower panels: NIH3T3 cells
infected with each indicated virus at MOI 2 for 24 hours were treated with a final concentration of 160 mM of prostratin for 30 minutes and then
harvested for immunoblot against phosphorylation of Thr202 and Tyr204 of Erk1/2. Blots were stripped twice to demonstrate equal amounts of
b-actin and comparable infection with expression of viral protein ORF65. C) 293T cells infected with the indicated viruses at MOI 1 for 24 hours were
lysed and analyzed for total amount of IFNAR1. Blots were stripped to demonstrate equal loading with b-actin, comparable infection with expression
of viral protein ORF65, and specificity of ORF54 to IFNAR1 with IGF1b. The same lysates were also subjected to immunoblot against IFNAR2. The
membrane was stripped twice to demonstrate equal loading with b-actin and comparable infection with expression of viral protein
ORF65.UI=uninfected; 54S=54Stop; DM=54DM.
doi:10.1371/journal.ppat.1002292.g004
A Conserved dUTPase has Critical Anti-IFN Activity
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to measure the transcript level of several ISGs, including MX1,
IFIT1, and IFIT3. In all cases, the ISG induction in cells infected
with 54Stop is higher than with infection by WT, 54DM, and
54R, suggesting ORF54 has a role in inhibition of type I IFN
responses (Figure 5B).
ORF54 is required for efficient growth in the presence of
type I IFN signaling
Although ORF54 is not essential for MHV-68 replication, the
54Stop virus exhibits a defect in STAT1 activation and
downregulating IFNAR1 expression. Hence, we speculated that
lack of ORF54 might have some effect on viral replication in cells
that are capable of producing and responding to type I IFN, such
as NIH3T3 cells. Indeed, as shown in Figure 6A, we found that the
54Stop virus has moderately attenuated multiple-step growth in
NIH3T3 cells (approximately 3.8-fold on day 4 and 4.1-fold
attenuation on day 5 post infection compared to WT). Moreover,
this attenuation of the 54Stop virus was not observed in Vero cells
(Figure 6A), which are unable to produce type I IFN in response to
infection [52]. To ensure this difference in phenotype of the
54Stop virus is due to its inability to block IFN signaling, we
infected bone marrow derived macrophages from wild-type and
IFN a/b receptor knockout (IFNAR-/-) mice at an MOI of 4. By
immunoblot of infected wild-type macrophages, we see a lower
production of the MHV-68 capsid protein, ORF65, with 54Stop
infection compared to WT, 54DM, and 54R infection. However,
the ORF65 production with 54Stop infection is rescued in the
IFNAR2/2 macrophages (Figure 6B). Similarly, the infectious
titer produced from wild-type macrophages infected with 54Stop is
between 6.3- to 7.5-fold lower than that of WT, 54DM, and 54R,
while the infectious titers produced from IFNAR2/2 macro-
phages are similar amongst all four virus types (Figure 6C). To
further demonstrate the role of ORF54 in antagonizing IFN
signaling during viral replication, virus production in NIH3T3
cells with or without the treatment of 100 units/mL of IFN-a was
compared (Figure 6D). The peak viral titers of WT, 54DM, and
54R viruses were relatively unaffected at this low dose, while the
average drop for 54Stop was 3-fold, p-value=0.022. The growth
defects observed with 54Stop in the presence of type I IFN
response demonstrate the role of ORF54 in antagonizing the
signaling pathway. The consistent, but modest, defects seen with
54Stop infection are also meaningful as it is known the virus has
multiple anti-IFN genes [34–38,53,54]. Additionally, all of above
in vitro viral replication results demonstrate that 54DM behaved
similarly to WT and 54R viruses but not to 54Stop, indicating that
the anti-IFN function of ORF54 is independent of its dUTPase
enzymatic function.
ORF54 plays a significant anti-interferon role during the
establishment of MHV-68 viral latency in vivo
We examined the role of ORF54 in vivo by infecting Balb/C mice
with WT MHV-68, 54Stop, 54DM, or 54R and measuring lytic
replication in the lungs on 5 and 7 days post infection (dpi) and the
establishment of latency at its peak on 14 dpi. Lytic infection does
not critically require ORF54. With intranasal infection we found
that lytic replication in the lungs at 5 dpi appears to be only slightly
affected by the lack of ORF54. The average infectious titer was
approximately3.5-to3.8-foldlowerwith 54Stopinfectionthanwith
WT MHV-68, 54DM, or 54R, with p-values 0.047, 0.002, and
0.018, respectively (Figure 7A). At 7 dpi the effects from the lack of
ORF54 on the lung viral titers were even smaller (1.2- to 1.8-fold
lower than others), and possibly insignificant with p-values of 0.048
for WT, 0.396 for 54DM, and 0.022 for 54R (Figure 7B). Similar
results and trends were obtained with analysis of the viral genome
copy number in the lung lysates (Figure S2). Infection of 54DM was
comparable to WT and 54R viruses, indicating that function(s)
other than dUTPase activity of ORF54 play a role, however minor,
during productive infection in the lung.
At 14 dpi, we analyzed the establishment of splenic latency by
performing an infectious center assay and quantifying viral
genome copy numbers of the spleens of mice infected with WT
MHV-68, 54Stop, 54DM, or 54R. The infectious center assay
quantifies the amount of latent virus that reactivates from a
population of B-cells upon ex vivo culturing. We found that the
54Stop virus has approximately 53- and 45-fold less reactivated
virus per 10
7 lymphocytes compared to WT and 54R viruses,
respectively (Figure 7C). Quantitation of the viral genome copies is
an unbiased measurement that does not rely on virus activity in the
assay itself, and it showed an even more pronounced reduction.
The 54Stop genome is almost undetectable, with 140- to 164-fold
lower genome copies than WT MHV-68, 54DM, and 54R
(Figure 7D). Lower levels of viral genome copies and infectious
centers suggest the defect of the 54Stop virus is in the
establishment of latency and not in the ability to reactivate. If
this drastic reduction in 54Stop latency is due to the inability of the
virus to block type I IFN signaling, we would expect to see latency
Figure 5. An ORF54-null virus infection promotes higher
induction of interferon stimulated genes. Bone marrow derived
macrophages from wild type mice were infected at an MOI of 2. Equal
infection was ensured by RT-PCR quantifying input viral genome copies
from total infected cellular DNA 1 hour after virus was introduced to the
culture. A) 24 hours post infection cells were harvested for immunoblot
against murine IFIT2. The blot was stripped to demonstrate equal
expression b-actin as a control. UI=uninfected; 54S=54Stop;
DM=54DM. B) 24 hours post infection, RNA was harvested and reverse
transcribed to cDNA. Transcripts for murine MX1, IFIT1, and IFIT3 were
measured by real-time PCR. The fold induction was calculated by first
normalizing each C(t) for the transcript to the actin C(t), and then
comparing to uninfected samples.
doi:10.1371/journal.ppat.1002292.g005
A Conserved dUTPase has Critical Anti-IFN Activity
PLoS Pathogens | www.plospathogens.org 6 October 2011 | Volume 7 | Issue 10 | e1002292Figure 6. ORF54-null virus has a moderate defect in the presence of type I IFN signaling. A) In these multiple-step growth curves, NIH3T3
or Vero cells were infected at MOI 0.01 and harvested for 5 consecutive days post infection. Viral titers were calculated by plaque assay following
three freeze and thaw cycles of the whole cell and supernatant lysate. This data is one representative from 3 independent trials. NIH3T3 curves are
shown in the left panel, Vero curves in the right. B) Bone marrow derived macrophages isolated from IFNa/b receptor knock-out mice and wild-type
controls were infected with each indicated virus at MOI 4. 60 hpi, cells were harvested and immunoblotted for viral late antigen ORF65. The blots
were stripped and re-probed for b-actin. UI=uninfected; 54S=54Stop; DM=54DM. C) Infection was completed as described in B. At 60 hpi, cells
were harvested and viral titers were calculated by plaque assay following three freeze and thaw cycles of the whole cell and supernatant lysate. The
assay was done in triplicate; averages are shown here with error bars reflecting one standard error. For 54Stop compared to WT, 54DM, and 54R,
p-values are 0.0004, 0.003, 0.0007, respectively. D) NIH3T3 cells were left alone or pretreated with 100 units/mL of IFN-a one day prior to infection by
each indicated virus at MOI 0.01. Immediately following and 2 days post infection, IFN-a was supplemented into the media at 100 units/mL in the
treated samples. On 4 days post infection, infected samples were harvested and subjected to three freeze and thaw cycles prior to titer by plaque
assay. The assay was done in triplicate; averages are shown here with error bars reflecting one standard error. For 54Stop compared to WT, 54DM, and
54R, p-values are 0.0007, 0.003, 0.008, respectively. For 54Stop, the p-value comparing untreated and IFN-a treated cells is 0.022.
doi:10.1371/journal.ppat.1002292.g006
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PLoS Pathogens | www.plospathogens.org 7 October 2011 | Volume 7 | Issue 10 | e1002292Figure 7. ORF54 non-dUTPase function is essential for establishment of latency in vivo, but not lytic infection. Balb/C mice were
infected with 500 pfu of each indicated virus. (A–B) Lung tissue was harvested for plaque assay to measure infectious titer. Infectious titer from lung
lysates at A) 5 dpi and B) 7 dpi. P-values for 54S compared to WT, 54DM, and 54R in A are 0.047, 0.002, 0.018, respectively and in B are 0.048, 0.396,
0.022, respectively. (C–D) At 14 dpi, splenocytes were harvested to C) measure infectious centers which are derived from reactivating virus and D)t o
determine viral genome copies from 100 ng of total splenocyte DNA. P-values for 54Stop compared to WT, 54DM, and 54R in C are 0.043, 0.0003,
0.005, respectively, and in D are 0.007, 0.042, and 0.040, respectively. P-value of 54DM compared to WT in C is not significant, p=0.159. E) IFNAR2/2
mice were infected with 500 pfu of 54Stop and 54R viruses. At 14 dpi, splenocytes were harvested to measure infectious centers, the p-value
between 54Stop and 54R is not significant, p=0.248, and F) viral genome copies determined from 100 ng of total splenocyte DNA, the p-value
between 54Stop and 54R is not significant, p=0.387. In all Figures, each m represents one animal, and a bar marks averages. For A,B n=4; for C,D n=6
except for WT virus where n=5; for E and F, n=5 for 54Stop and n=6 for 54R.
doi:10.1371/journal.ppat.1002292.g007
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receptor. Indeed, in IFNAR2/2 mice splenic latency of 54Stop
at 14 dpi is greatly increased to a level similar to 54R virus; the
number of infectious centers with 54Stop infection is 2.8-fold
lower than with 54R, but with a statistically insignificant p-value of
0.248 (Figure 7E). Viral genome copies of 54Stop and 54R viruses
from IFNAR2/2 mice splenocytes are nearly identical
(Figure 7F). Our results indicate that ORF54 is required for
establishing a latent infection, and this requirement is based on its
anti-IFN activity as the deficiency of 54Stop is rescued in mice
unresponsive to type I interferon. This result concludes that the
major role of ORF54 for establishing and/or maintaining latency
is to inhibit type I interferon responses.
Discussion
Viral pathogens have adapted several avenues of immune
evasion, including inhibition of the innate immune response. The
importance of the interferon system is highlighted by the multiple
evasion strategies employed by viruses, such as herpesviruses
[14,55]. Here we present a report on ORF54, a conserved viral
dUTPase, identified by our unbiased screen designed to isolate
gammaherpesvirus ORFs involved in the inhibition of the type I
IFN induced signaling pathway. Interestingly, ORF54 enzymatic
activity proves dispensable for its anti-IFN function. Using KSHV
ORF54 we were further able to demonstrate the anti-IFN role of
ORF54 is conserved amongst KSHV and MHV-68. We have
found that when high levels for ORF54 are present, either by
ectopic expression or by infection with MHV-68, the total amount
of cellular type I interferon receptor 1 is reduced, causing
depression of the type I IFN response. Finally, through
manipulation of the viral genome and murine host, we uncovered
the biologically relevant function that ORF54 plays in not only
blocking a critical component of the innate immune response, but
also in persistent infection of gammaherpesviruses.
The most surprising and significant finding of our study is that
the primary role of ORF54 during MHV-68 infection of cells and
mice appears to be its anti-IFN function rather than its dUTPase
activity. In three separate cell culture systems where type I IFN
signaling is functioning, we demonstrate attenuation of the 54Stop
virus, but not 54DM, a dUTPase-null virus (Figure 6). None of the
defects seen with the 54Stop virus are observed with 54DM
infection, indicating that the dUTPase activity is dispensable for
the role of ORF54 during MHV-68 replication in cultured cells. In
mice, while the 54Stop virus has a relatively normal productive
infection in the lung, it shows a very strong deficit in spleen latency
that is not found in the dUTPase-null virus (Figure 7C, 7D).
However, this deficit is largely rescued in IFNAR2/2 mice
(Figure 7E), supporting the conclusion that it is the anti-IFN but
not the dUTPase activity of ORF54 that plays a major role for
MHV-68 establishment of latent infection of mice.
Across eukaryotes, prokaryotes, and viruses, dUTPases are
highly conserved proteins, especially at the structural level [56].
Most eukaryotic dUTPases have 5 conserved motifs ordered 1–5
from the N- to C- terminal [45,48,49]. Functional dUTPases are
formed as homotrimers containing three complete active sites
formed from motifs 1–5 of each protein [45,49]. However, the
herpesvirus monomer is an active dUTPase with one active site
formed by motifs 1–5 [48,57]. The herpesvirus dUTPase protein
sequence is twice as large as the cellular, with the C-terminal half
containing domains 1, 2, 4, and 5 [48] and a herpesvirus unique
domain called motif 6 between motifs 2 and 4. Towards the center
of the protein, there is an actual motif 3, that was maintained after
the loss of motifs 1, 2, 4, and 5 from the N-terminal portion
[45,48]. By examining the ability of murine cellular dUTPase to
inhibit type I IFN signaling in our reporter assay, we found that
dUTPase activity alone does not diminish IFN-a induced
activation of ISRE, while an ORF54 dUTPase-null mutant still
does (Figure 1). Therefore, it is possible that the N-terminal half of
ORF54 may have evolved the additional function of type I IFN
inhibition. For the gammaherpesviruses MHV-68, KSHV, and
EBV, the ORF54 motif 3 starts at amino acid 82, 78, and 73,
respectively. Since the motifs required for active site formation are
found by the C-terminal halves of each protein, the N-terminal
portion upstream of motif 3 in herpesviral dUTPases contain no
recognizable or conserved sequences from cellular dUTPases. The
sequences in the N-terminal half of ORF54 demonstrate some
conservation between the gammaherpesviruses examined, but
further studies designed to functionally map ORF54 anti-IFN
activity are required to identify such a domain. ORF54 is an early
protein [58] that, like other viral dUTPases, is expressed in both
the cytoplasm and nucleus of infected cells, while cellular
dUTPases are only found in the nucleus and mitochondria of
cells [59]. Using a recombinant MHV-68 with a FLAG epitope
tag on ORF54 to study its expression kinetics, we found that
during early stages of infection ORF54 appears evenly distributed,
but has preference for the nucleus at late stages of virus replication
when cytopathic effect is obvious (Figure S3). As the MHV-68
genome is replicated in the nucleus, perhaps ORF54 functions as a
dUTPase in the nucleus to help maintain genomic integrity and as
an inhibitor of type I IFN signaling in the cytoplasm. It would be
informative to identify ORF54 protein interaction partners in both
compartments and at the various stages of virus infection.
Interestingly, beta- and gammaherpesviruses contain several
ORFs with dUTPase-related domains that demonstrate strong
divergence, where besides their catalytic motifs they exhibit
different functions [48], some involving innate immune responses.
Betaherpesviruses are unique in that many do not have a single
ORF with dUTPase catalytic activity [60,61]. However, several
betaherpesvirus ORFs exist with dUTPase-related domains, such
as UL72, UL82, UL83, UL84, and UL31 [48]. Human
cytomegalovirus (HCMV) encodes pp65, also called UL83, that
contains the dUTPase-related domain motif 6 [48]. HCMV pp65
expression led to the inhibition of phosphorylation of IRF3 and to
its sequestration in the cytoplasm following induction of the IFN
pathway [62,63]. In gammaherpesviruses, although ORF54 is the
only functional dUTPase, ORFs 10 and 11 both contain the
dUTPase-related domain motif 6 [45,48]. Here we showed in a
transient transfection reporter assay that KSHV ORF54 is capable
of reducing IFN-a responses (Figure 1). However, EBV ORF54
was found to induce expression of several pro- and anti-
inflammatory cytokines when cells were treated with purified
EBV ORF54 [64–67]. The biological significance of immune
modulation by EBV ORF54 in the context of virus infection
remains to be determined. KSHV ORF10 is a viral lytic protein
that blocks IFN signaling by forming inhibitory complexes with
JAK1 and TYK2 [35]. EBV ORF11 (LF2) was found to bind to
IRF7 to inhibit dimerization and IRF7-mediated activation of type
I IFN production, in a manner unrelated to its dUTPase domain
[54]. Previously, we also found that MHV-68 ORF11 has a similar
effect to ORF54 in inhibiting ISRE reporter induction by IFN-a
[34]. Therefore, it is possible for large DNA viruses, such as
herpesviruses, to utilize multiple proteins to inhibit type I
interferon responses. This is further supported by the observation
that STAT1 activation upon IFN-a treatment is not fully
recovered in cells infected with the 54Stop virus (Figure 4B),
indicating the presence of other viral proteins with overlapping
anti-IFN functions.
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anti-IFN function of ORF54, but they also raise a question about
the biological role of its dUTPase activity. Numerous RNA and
DNA viruses, such as retroviruses, poxviruses, and herpesviruses,
encode a functional dUTPase in their genomes, suggesting its
importance for the viral life cycle [45,68,69]. However, viral
dUTPases are generally dispensable for virus replication
[50,70,71], likely because cellular dUTPase is readily available
and active in most dividing cells. Many cellular enzymes involved
in DNA replication and nucleotide metabolism are strongly cell-
cycle dependent. Therefore, it is presumably advantageous for the
virus to encode its own enzymes for genome replication in
terminally differentiated and non-dividing cells where the cellular
counterparts may not be available. For example, herpesviruses
encode several other enzymes in addition to dUTPase, such as
thymidine kinase (TK), exonuclease, Uracil-DNA glycosylase
(UNG), and ribonucleotide reductase (RR). For MHV-68, these
viral enzymes are not required for in vitro virus replication in
actively dividing cultured cells, but disruption of TK or RR leads
to severe attenuation in acute productive infection in the lung as
well as in splenic latency [50,72,73]. However, because site-
specific mutations targeting the enzymatic activity of these proteins
were not used in these studies, it cannot be completely excluded
that other possible mechanisms unrelated to their known TK or
RR functions account for the observed severe attenuation.
In this study, we constructed a dUTPase-null virus, 54DM, to
study the specific contribution of the enzyme activity of ORF54.
Interestingly, unlike with TK and RR, lack of dUTPase activity or
even the entire ORF54 protein does not detrimentally retard virus
replication in the lungs of infected mice. Previous studies in our lab
have found that ORF54-null viruses constructed with a large
transposon insertion cause a more significant defect on lytic
replication in the lungs of infected mice [50]. This discrepancy
may be due to the large disturbance each transposon causes in the
highly compact MHV-68 viral genome, where most promoter
regions overlap coding regions. The ORF54-null virus, 54Stop,
shows a very strong defect in the infectious center assay that is not
found with the dUTPase-null virus, implying that the lack of
ORF54 enzymatic activity does not dramatically hinder the
establishment of the MHV-68 latent load, while lack of the entire
protein does. However, mice infected with 54DM do have a slight,
but statistically insignificant, reduction in the amount of
reactivated virus from infected splenocytes, at 2.8- and 2.4-fold
defect compared to WT and 54R viruses, respectively (Figure 7C).
This marginal defect of 54DM was not observed when the viral
genome copy number was analyzed (Figure 7D), thus it is possible
that the phenotype seen in the infectious center assay is due to the
lack of dUTPase during reactivation. The 54Stop virus lacks any
expression of ORF54, including its dUTPase activity, and the 2.8-
fold reduced level of infectious centers compared to 54R in
IFNAR2/2 mice mirrors that seen with 54DM virus during
reactivation in Balb/C mice. Indeed, as with 54DM in wild-type
mice, 54Stop has nearly identical viral genome copies as 54R in
the splenocytes of IFNAR2/2 mice, again suggesting that the
minor defect in the infectious center assay is due to reactivation.
Although it was expected that dUTPase-null viruses grow
normally in actively dividing cell culture, it is surprising that the
only phenotype we observed in mouse infection is a moderate
defect in reactivation from latency. However, our observation is
not unique. Following in vivo infection, HSV-1 dUTPase mutants
replicate like wild type in the footpad, sciatic nerve, and dorsal
root ganglia; a defect of about 10- to 100-fold is only visible when
the virus moves to the CNS spinal cord. These dUTPase mutants
were able to establish latent infections but demonstrated a defect in
reactivation from latency [74]. Taken together, our results indicate
that the dUTPase activity of ORF54 does not have a significant
role during MHV-68 productive infection in the lung or latency in
the spleen. However, our interpretation for the maintenance of
dUTPase in the viral genome is that dUTPase activity is likely
required for genome stability over many generations. Further-
more, reactivation is considered much less effective than lytic
replication in permissive cells, thus a less optimal replication
environment may have a more profound effect on the reactivation
process over time.
Gammaherpesviruses are characterized by their ability to
establish latent infection in lymphocytes. Establishment of viral
latency first requires the efficient infection of lymphocytes. By
affecting persistent infection of gammaherpesviruses, the IFN
response has far reaching effects on the viral life cycle and the
establishment of latency, instead of only acting primarily on initial
infection. Furthermore, the type I IFN response is critical in
shaping the adaptive immune response [1,2,6,9,36]. Altering the
balance between the host immune response and viral immune
evasion genes could drastically affect the overall outcome of viral
infection. The anti-IFN function of ORF54 appears to be
relatively dispensable for lytic replication in vitro and in vivo, but
absolutely required for the establishment of latency. As a whole,
our data suggests that evading the type I IFN response is critical
for the establishment of latent infection in lymphocytes and that
ORF54 plays a major role in this evasion. The reduced latency
observed in the infection of 54Stop may be due to the inability of
the virus to replicate well in a particular cell type, such as
lymphocytes, that is more sensitive or responsive to the anti-viral
effects of IFN. Although several genes are likely required and may
have some overlapping functions, lack of one of these genes, such
as ORF54, retards establishment of latent infection. Our results in
IFNAR2/2 mice not only emphasize the importance of ORF54
in the type I IFN pathway by demonstrating a rescue in an
infectious center assay, but also hint at the necessity of this host
pathway in blocking the establishment of latent infection in
lymphocytes. However, the mechanisms by which the virus
spreads from the inoculation and lytic replication sites to the
latency compartment remain largely elusive. Thus, although our
data suggests its importance, we are currently unable to isolate at
which stage during this viral spread the anti-IFN function of
ORF54 is required. Analysis with a detailed time course and
different cell types is required to further understand the interaction
between type I interferon responses and latency establishment.
Defining immune evasion strategies employed by MHV-68 will
allow better design of a live attenuated vaccine to human
gammaherpesviruses KSHV and EBV. One strategy to increase
the success of a vaccine is to limit the establishment of latency and
increase its immunogenicity by removal of viral immune evasion
genes [75]. Because ORF54 is not required for virus replication,
plays a role in type I IFN inhibition, and is necessary for the
efficient establishment of latency, a virus lacking ORF54, as well as
other immune evasion genes and genes required for latency, is a
promising vaccination strategy.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the Public Health Service (National
Institutes of Health). The protocol was approved by the
Institutional Review Board and Animal Research Committee of
the University of California Los Angeles (assurance of compliance
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ketamine and xylazine anesthesia and all efforts were made to
minimize suffering.
Cells
293T and Vero cells were cultured in complete Dulbecco’s
modified Eagle medium (DMEM) containing 10% FBS. NIH3T3
cells were cultured in DMEM containing 10% BCS. Bone-marrow
derived macrophages (BMDM) from both wild-type and IF-
NAR2/2 mice were immortalized by v-raf and c-myc oncogenes,
cultured in RPMI containing 10 mM HEPES, 10% FBS, and
MCSF, and were a kind gift from Shankar Iyer (Genhong Cheng
Lab, UCLA). All culture medium was also supplemented with
penicillin and streptomycin and all cells were cultured at 37uC
with 5% CO2.
dUTPase assay for enzymatic activity
dUTPase assay was adapted and modified from previous
methods used to measure enzymatic activity [44,59,76]. Briefly,
each potential FLAG-tagged dUTPase construct was transfected
into 293T cells using Lipofectamine 2000 (Invitrogen). 48 hours
post transfection, cells were lysed with buffer containing 100 mM
Tris pH 7.5, 50 mM NaCl, and 1% NP-40, supplemented with
1 mM PMSF, 1 mg/mL Aprotinin, 1 mg/mL Leupeptin, 1 mg/mL
Pepstatin A, 1 mM Na3VO4, and 1 mM NaF. Lysates were kept
on ice for 10 minutes and clarified with a high speed spin at 4uC
for 15 minutes. FLAG-tagged proteins were immunoprecipitated
by incubating lysates with Protein G Sepharose (GE Healthcare
17061801) and 4 mg of anti-FLAG antibody (Sigma F3165),
followed by elution from the antibody by incubation with 20 mgo f
36FLAG peptide (Sigma F4799). 5 ul of purified FLAG-tagged
proteins were incubated at 37uC with 5 ul of 5 mM dUTP
(Promega U1191) for 0, 2, 5, 10, 15, 20, and 25 hours in 10 ul of
26 reaction buffer comprised of 100 mM Tris pH 7.5, 20 mM
MgCl2, 20 mM DTT, and 0.2 mg/mL BSA. Reactions were
terminated by freezing. Potentially digested dUTP are at a
maximum final concentration of 1.25 mM, lower if digested. PCR
was conducted using MHV-68 BAC DNA as a template, with
primers to amplify a region in ORF57 (forward primer: 59-
ACTGAAACCTCGCAGAGGTCC-39 and reverse primer 59-
GCACGGTGCAATGTGTCACAG-39) using the potentially
digested dUTP alongside dATP, dCTP, and dGTP. Cycle
conditions were 95uC 5 min; 95uC 30 seconds, 60uC 30 seconds,
72uC 30 seconds for 35 cycles; 72uC 10 minutes; hold at 4uC.
PCR products were run on a 3% agarose gel.
Generation of recombinant MHV-68
The recA
+ Escherichia coli (E. coli) strain GS500 harboring a BAC
containing the wild-type MHV-68 genome was used to construct
recombinant MHV-68 by allelic exchange with the conjugation
competent E. coli strain GS111 containing a suicide shuttle plasmid
pGS284, as previously described [34,77,78]. For each recombi-
nant MHV-68, overlap extension PCR was used to construct a
unique shuttle plasmid pGS284 harboring the desired mutation
with a 500 base pair flanking region. To screen for the correct
mutation, restriction enzyme digests were performed on PCR
products amplified with the outer primer sets on the BAC MHV-
68 clones. WT MHV-68 and 54R contain a BamHI restriction
enzyme site that is altered to a HindIII site in 54Stop. The base
pair changes in 54DM allow the introduction of an AseI site that is
absent in WT MHV-68. Following selection of the desired
recombinant clone, the MHV-68 BAC DNA was purified and
transiently transfected with Lipofectamine 2000 into 293T cells
with an equal amount of a plasmid expressing Cre recombinase to
remove the BAC sequence. Three days post transfection, a single
viral clone was isolated by limiting dilution and propagated for
future studies. Produced viruses were quantified by plaque assay
and limiting dilution. Genomic integrity of the final recombinant
viruses was analyzed by SmaI and EcoRI restriction enzyme
digestion and Southern blot with DIG-labeled DNA probes to the
whole genome or 6 kb of the left end (Roche 11585614910).
Primers used for the construction of each shuttle plasmid are listed
59 to 39 as follows: 54R and 54Stop, outer primers: CAGGACA-
GATCTCACTAGACACTGTGACTATAGAC and CTGTCC-
CCCGGGTAGCAGACACAGGTCCTCAG; 54Stop, inner
primers: CACATAACTGAGTAAGCTTACCAGACTAAAAT-
TTCAAAACATCAC and TGGTAAGCTTACTCAGTTAT-
GTGCCTTGTGTAGTTAGGGCC; 54DM, outer primers:
GAAGAGATCTCACTCCCCCACTGAGGGACGTATGTG-
TCAGC and GTTGGCTAGCCAATTTCAGACTTGTCTG-
CAGCTTCGTGCGGAACCCTAATAAAC; 54DM, inner prim-
ers: ATTAATCAGTCCAGTTGCGCCGGTGACGAGACTG-
TT and GCAACTGGACTGATTAATCCCGGCTACCGGG-
GTGAAAT.
MHV-68 virus quantification
MHV-68 concentrated virus was titered using plaque assay and
limiting dilution. For plaque assay, 10-fold serial dilutions of each
virus were incubated on a monolayer of Vero cells for 1 hour. The
infected cells were overlaid with 5% methylcellulose DMEM. At 6
days post infection, cells were fixed with 2% crystal violet in 20%
ethanol. Plaques were counted at the optimum dilution to
calculate virus titer. To determine the 50% Tissue Culture
Infectious Dose (TCID50), 12 wells seeded with Vero cells in a 96-
well plate were infected by 100 ul of each 10-fold serial dilution. 7
to 10 days post infection, every well was scored for cytopathic
effect (CPE). TCID50 was determined by the calculation TCID50/
mL=10610‘[(highest dilution with 100% CPE)2[0.5+((# of
wells with CPE/total wells) in next highest dilution)+(each
following dilution’s CPE fraction)]]. Viral titers of multiple step
growth curves were quantified by plaque assay.
Plasmids
Wild-type MHV-68 BAC was constructed as previously
described [34]. The firefly luciferase reporter driven by the
interferon-stimulated response element (ISRE_firefly-luciferase)
and the renilla luciferase reporter driven by the promoter of
housekeeping gene phosphoglycerate kinase (PGK_renilla-lucifer-
ase) were kind gifts from Dr. Genhong Cheng and Dr. Lily Wu,
respectively (UCLA). All MHV-68 open reading frames were
cloned into pENTR (Invitrogen) by PCR amplification from
MHV-68 DNA, then transferred to a modified destination vector
resulting in a 36FLAG epitope tag at the N-terminus. Specifically,
for MHV-68 ORF54, primers used are 59-CCGAGCGAATT-
CAATGAAAGTGGAATACTCCTTTGTG-39 and 59-
GCTCGGGGTACCTTAATTCACCCCACTTGACCCAAAC-
39. To construct ORF54 MHV-68 H80A/D85N by overlap
extension PCR, the same inner primers as for 54DM virus were
used, the outer primers used are 59-CCGAGCGAATTCAAT-
GAAAGTGGAATACTCCTTTGTG-39 and 59- GCTCGGG-
GTACCATTCACCCCACTTGACCCAAAC -39. Wild-type
ORF54 and ORF54 H80A/D85N have slightly different molec-
ular weights due to the cloning process of FLAG-ORF54 H80A/
D85N. A modified Gateway cloning system (Invitrogen) was
utilized to generate entry clones of the target protein, then
recombined by an LR reaction into the same destination vector as
FLAG-ORF54. This process inserted 6 additional amino acids to
the N-terminus of the protein (from the multiple cloning site) after
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site. Also, the H80A/D85N clone utilizes a STOP codon in the
destination vector while the FLAG-ORF54 clone includes the
endogenous STOP codon. Therefore, 10 additional amino acids
(from the multiple cloning sites) are added to the C-terminus of
FLAG-ORF54 H80A/D85N. In total, the FLAG-ORF54 H80A/
D85N protein has an additional 16 amino acids, or approximately
1.7 kDa additional molecular weight, compared to the wild type
FLAG-ORF54.These changes demonstrated no effect on ORF54
or ORF54 H80A/D85N function. KSHV ORF54 was cloned
from the a KSHV BAC construct, a kind gift from Dr. Jae Jung
(University of Southern California). The primers used are 59-
TAATGGATCCATGAACAACCGCCGAGGCTC-39 and 59-
TAATGTCGACCTAAAACCCAGACGACCCCAG-39.
Promoter reporter assay
293T cells were seeded at 5610
4 cells per well in a 48-well plate
16 hours prior to transfection. Cells in each well were transfected
using Lipofectamine 2000 (Invitrogen), with 20 ng of ISRE_firefly-
luciferase, 5 ng of PGK_renilla-luciferase, 200 ng of viral ORF or
vector control, and 175 ng of filler DNA. 24 hours post
transfection, identically transfected wells were left untreated or
were treated with 3610
4 units of human interferon-a (both human
and mouse IFN-a are purchased from pbl Interferon Source).
24 hours post treatment, both firefly and renilla luciferase activity
was measured (Promega Dual-Luciferase Assay Kit). Fold
activation was calculated by first normalizing all values to their
internal renilla luciferase control, and then by dividing luciferase
activity in the treated samples by that of the untreated samples.
Expression of viral ORFs was determined by immunoblot against
the FLAG epitope expressed at the N-terminus of each of the
ORFs in our MHV-68 expression library.
Immunofluorescence assay
NIH3T3 cells were seeded in 24-well plates and infected with
FLAG-54 MHV-68 at an MOI of 1. Cells were fixed and
permeabilized with treatment for 30 minutes at room temperature
with 100% methanol. Cells were then washed in three changes of
PBS and stored in PBS until staining. Mouse anti-FLAG M2
(Sigma F3165) was incubated with cells overnight for 16 hours at a
dilution of 1:750, and Alexa Fluor 594 goat-anti mouse IgG
(Invitrogen A11005) at a dilution of 1:1000 was incubated with
cells for 1 hour. Hoechst dye was added for 10 minutes prior to
analysis.
Immunoblot
Cells were lysed for 10 minutes on ice in lysis buffer (50 mM
Tris pH 7.5, 1% NP-40, 0.25% sodium deoxycholate, 150 mM
NaCl, 1 mM EDTA) supplemented with 1 mM PMSF, 1 mM
Na3VO4, and 1 mM NaF. Lysates were then combined with 46
protein sample buffer (0.25 M Tris pH 6.8, 8% SDS, 40%
glycerin, 20% b-mercaptoethanol, 0.008% Bromophenol blue),
sonicated, and boiled for 10 minutes prior to loading on a 10%
polyacrylamide gel. Membranes were stripped with Multi-Western
Stripping buffer (Bioland Scientific), prior to re-probing with each
subsequent antibody. The antibodies used in this study were rabbit
anti-human phosphoSTAT1 (Cell Signaling 9167), rabbit anti-
mouse phosphoSTAT1 (Millipore 07307), rabbit anti-total
STAT1 (Cell Signaling, 9175S), mouse anti-FLAG M2 (Sigma
F3165), rabbit anti-human IFNAR1 (Abcam, ab45172), mouse
anti-b-actin (Sigma A5316), rabbit anti-IGF-1 Receptor b (Cell
Signaling 3027S), rabbit anti-IFNAR2 (Novus Biologicals 31665),
rabbit anti-phosphoErk1/2 (Cell Signaling 4376), and rabbit anti-
IFIT2 (Abcam 55837). Rabbit serum against viral lytic protein
ORF65 was derived in our lab. Secondary antibodies conjugated
to HRP were donkey anti-rabbit IgG (GE Healthcare NA934V)
and sheep anti-mouse IgG (GE Healthcare NXA931).
Real-time PCR
Total RNA was extracted from cells by RNeasy Mini Kit
(Qiagen) and reverse transcribed into cDNA by qScript cDNA
Synthesis Kit (Quantas). Primers used in RT-PCR to quantify
cellular transcripts are as follows: actin: 59-GTATCCTGACCCT-
GAAGTACC-39 and 59-TGAAGGTCTCAAACATGATCT-39;
human IFNAR1: 59- AACAGGAGCGATGAGTCTGTC-39 and
59- TGCGAAATGGTGTAAATGAGTCA-39; murine IFNAR1:
59- AGACGAGGCGAAGTGGTTAAA-39 and 59- GCTCTGA-
CACGAAACTGTGTTTT-39; murine MX1: 59-GAATAAT-
CTGTGCAGGCACTATGA-39 and 59-CTCTCCACTCCT-
CTCCTTCTTTC-39; murine IFIT1: 59-TGCTTTGCGAAGG-
CTCTGAAA-39 and 59-TTCTGGATTTAACCGGACAGC-39;
murine IFIT3: 59-AGTGAGGTCAACCGGGAATCT-39 and 59-
TCTAGGTGCTTTATGTAGGCCA-39.
In vivo assays
All in vivo procedures were performed according to protocols
approved by the University of California, Los Angeles, the Animal
Research Committee, and the Institutional Review Board. Balb/C
mice were purchased from Charles River Laboratories. IFNAR2/2
mice were a kind giftfromDr.Genhong Cheng at UCLA.Mice were
intranasally infected with 500 pfu under sedation by I.P. injection of
2 mg ketamine and 0.04 mg xylazine. At 5 and 7 days post infection,
mice were sacrificed and lung tissue was harvested in 1 mL of
complete DMEM. Lung tissue was homogenized to measure the viral
titer by plaque assay. At 14 days post infection, mice were sacrificed
for infectious center assay of splenocytes. Briefly, a single cell
suspension was isolated from the spleen of each infected animal. The
splenocytes were co-cultured for one day with a monolayer of Vero
cells, then overlaid with 5% methylcellulose DMEM for 6 additional
days prior to fixing cells with 2% crystal violet in 20% ethanol. Each
viral plaque reflects MHV-68 reactivated from splenocytes. Plaques
were counted at the optimum dilution and number of infectious
centers calculated per 1610
7 splenocytes. To determine viral genome
copies, total genomic DNA for quantitative-PCR was harvested from
lung lysates and splenocytes using QiaAmp DNA Mini Kit (Qiagen).
The PCR reaction was comprised of 100 ng of total genomic DNA as
a template and the primers used were 59-ACCTTGAAACCCGT-
GAAGG-39 and 59-CATCTGCCACGACCTGAGAT-39.
Gene ID numbers
Swiss-Prot accession numbers for the proteins/genes used in this
study are as follows: MHV-68 ORF54, P88991; KSHV ORF54,
P88942; MHV-68 ORF48, P88986; and murine cellular dUTPase
(DUT), Q9CQ43. The MHV-68 viral genome GenBank accession
number is U97553.2.
Supporting Information
Figure S1 ORF54 does not alter the transcript level of
IFNAR1 during infection. 293T and NIH3T3 were infected at
MOI 1 for 24 hours, and bone marrow derived macrophages from
wild type mice (BMDM) were infected at MOI 2 for 24 hours.
Equal infection was ensured by RT-PCR quantifying input viral
genome copies from total infected cellular DNA 1 hour after virus
was introduced to the culture. RNA was harvested and reverse
transcribed to cDNA. Human (293T) and murine (NIH3T3,
BMDM) IFNAR1 transcript levels were quantified by RT-PCR,
normalized first to actin, and are shown relative to uninfected cells.
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infection are not significant for any of the three cell types.
UI=uninfected.
(TIF)
Figure S2 Viral genome copies isolated from infected
lung lysates. Balb/C mice were infected with 500 pfu of each
indicated virus. Lung tissue was harvested for isolation of DNA to
measure viral genome copy number by quantitative RT-PCR at A)
5 dpi and B) 7 dpi. P-values for 54S compared to WT, 54DM,
and 54R in A are 0.025, 0.013, 0.003, respectively and in B are
0.561, 0.052, 0.190, respectively.
(TIF)
Figure S3 Expression kinetics and localization of
ORF54 during infection. NIH3T3 cells were infected at
MOI 1 with an MHV-68 recombinant virus with an N-terminal
FLAG tag on ORF54. A) Immunoblots against FLAG epitope
demonstrate ORF54-FLAG expression. Immunoblot was stripped
and re-probbed for b-actin as a control. B) Immunofluorescence
assay demonstrating the localization of ORF54-FLAG during
infection. Hoechst was used to stain nuclei. UI=uninfected cells,
hpi=hours post infection.
(TIF)
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